The aim was to evaluate the effectiveness of intravenous ondansetron as compared to intravenous metoclopramide in hyperemesis gravidarum.
INTRODUCTION
+\SHUHPHVLV JUDYLGDUXP +* LV FKDUDFWHUL]HG E\ severe nausea and vomiting, inability to tolerate IRRG RU ÀXLGV DQG WKH SUHVHQFH RI NHWRQXULD 1 The VHYHULW\ FDQ EH TXDQWL¿HG ZLWK WKH 3UHJQDQF\ 8QLTXH 4XDQWL¿FDWLRQ RI (PHVLV 384( 6FRUH 7DEOH 2 which has been validated and shown to correlate with clinical outcomes. 3 Treatment for HG is supportive and the aims are to manage the symptoms of nausea and vomiting, correct dehydration and electrolyte abnormality and prevent complications. There have been very few randomized control trials to evaluate and compare the effectiveness or safety of different antiemetics for HG. 4 +HQFH WKLV VWXG\ ZDV GHVLJQHG ZLWK WKH VSHFL¿F objective to compare the effectiveness of intravenous ondansetron versus metoclopramide with respect to LPSURYHPHQW RI WKH 384( VFRUH GXUDWLRQ RI KRVSLWDO VWD\ GXUDWLRQ RI LQWUDYHQRXV ÀXLG WKHUDS\ QXPEHU RI doses of intravenous medication, weight gain during treatment.
METHODS
It was a randomized controlled trial conducted on SDWLHQWV DGPLWWHG WR J\QHFRORJ\ ZDUG IRU WKH ¿UVW time in their current pregnancies with presumed hyperemesis gravidarum during the study period of RQH \HDU $SULO ± 0DUFK DQG PHHWLQJ WKH inclusion criteria. A convenience sample size was used with a plan to enroll 30 patients in each arm. First 60 patients were enrolled using computer generated random number table. All additional patients were allotted in each arm alternately. The study was started DIWHU HWKLFDO FOHDUDQFH IURP WKH ,QVWLWXWLRQDO (WKLFDO Review Board and written informed consent from the patients enrolled in the study. The study design has been illustrated in Figure 1 . All the pregnant patients with hyperemesis occurring GXULQJ WKH ¿UVW RU HDUO\ VHFRQG WULPHVWHU ZHHNV who met the following criteria were included in the study: inability to hold food, ketonuria, electrolyte DEQRUPDOLWLHV ZHLJKW ORVV NJ LI ZHLJKW GRFXPHQWHG WZR YLVLWV WR 23' UHTXLULQJ WUHDWPHQW for emesis. The following patients were excluded: patients who could be managed on outpatient basis, patients with eating disorder, previous psychiatric diagnosis, patients with previous hospitalization for HG in current pregnancy and refusal to consent. For all patients recruited into the study, a detailed history reviewing the severity of symptoms, 
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RESULTS
The total number of admissions for HG was 81 out of ZKLFK ZRPHQ ZHUH KRVSLWDOL]HG IRU WKH ¿UVW WLPH while 13 patients had readmissions. These 68 patients were randomized 34 in each group. The baseline characteristics of both the groups were comparable 7DEOH Figure 2 .
Figure 2. Comparison of the daily mean PUQE scores of the two groups (n=68).
Applying the paired t-test, the mean difference EHWZHHQ WKH DGPLVVLRQ DQG GD\ 384( VFRUHV ZDV 5.38 ± 2.11 for the ondansetron group and 5.65 ± 2.30 for the metoclopramide group and the difference was QRW VLJQL¿FDQW ZKHQ WKH WZR JURXSV ZHUH FRPSDUHG WR HDFK RWKHU ([FOXGLQJ WKH SDWLHQWV ZKR IDLOHG WR respond adequately by 96 hours of treatment (N1=1, 1 WKH GLIIHUHQW WUHDWPHQW SDUDPHWHUV RI WKH WZR groups have been compared as in Table 4 . 8 In a study done at Nepal medical college teaching hospital, the incidence of HG was 2.5% of all pregnancy. 9 In this study, the admission IRU K\SHUHPHVLV Q LQFOXGLQJ UHDGPLVVLRQV was found to be 10.64% of total early pregnancy DGPLVVLRQV IRU DQ\ SUHJQDQF\ FRPSOLFDWLRQ Q All the patients had moderate to severe disease at SUHVHQWDWLRQ WKH PHDQ 384( VFRUHV EHLQJ 1.59, which is expected since HG is considered to be the end of the spectrum of NVP. The mean duration of hospital stay was 3.22 ± 1.48 days. In another study the range of hospital stay was 1-10 days with mean hospital stay 2.26 days. 9 There were no statistically VLJQL¿FDQW GLIIHUHQFHV LQ WKH SUHVHQFH RI ULVN IDFWRUV among the patients in each group, the admission 384( VFRUH GHQRWLQJ WKH VHYHULW\ RI GLVHDVH DQG WKH baseline investigation between the two groups. This shows that both groups were highly homogenous in their composition, adding tremendous statistical value to the study.
Prior to this study, there has been no published study to compare the effectiveness of ondansetron and metoclopramide in HG. The hypothesis of this study was that therapy with ondansetron was better than metoclopramide in the management of HG in terms RI GXUDWLRQ RI KRVSLWDO VWD\ GXUDWLRQ RI LY ÀXLGV weight gain during treatment, number of doses of LY PHGLFDWLRQ XVHG DQG LPSURYHPHQW LQ WKH 384( scores. However, when the two groups were compared QR VWDWLVWLFDOO\ VLJQL¿FDQW GLIIHUHQFH ZDV IRXQG LQ WKH outcome variables. In a preliminary investigation done by Sullivan, 10 ondansetron offered no advantage when compared with promethazine in the relief of nausea, weight gain, days of hospitalization (4.5 ± YV DQG WRWDO GRVHV RI PHGLFDWLRQ SHU KRVSLWDOL]DWLRQ YV 7KH UHVXOWV RI WKH SDWLHQWV YLVXDO DQDORJ VFRUHV VKRZHG QR difference between the two drugs. Daily weight gain progressed equally in the two groups. In the present study the median number of days of hospital stay in RQGDQVHWURQ JURXS ZDV ,45 QXPEHU RI GRVHV RI LY PHGLFDWLRQ 384( VFRUH ZDV used in this/our study.
In a randomized controlled trial, 11 promethazine and metoclopramide have similar therapeutic effects in patients who are hospitalized for hyperemesis gravidarum. The median vomiting episodes were RQH UDQJH ± FRPSDUHG ZLWK WZR UDQJH ± (p= DQG ZHOOEHLQJ YLVXDO QXPHULFDO UDWLQJ VFDOH VFRUHV ZHUH UDQJH ± FRPSDUHG ZLWK UDQJH ± p=0 IRU PHWRFORSUDPLGH and promethazine respectively. Repeat-measures analysis of variance of the nausea visual numerical UDWLQJ VFDOH VFRUHV VKRZHG QR VLJQL¿FDQW GLIIHUHQFH between study drugs (F score = 0.842, p ,Q P\ study the median number of days of hospital stay in PHWRFORSUDPLGH JURXS ZDV ,45 QXPEHURI GRVHV RI LY PHGLFDWLRQ ,45 7KH 384( VFRUH was 6.88 ± 2.18 at end of 24 hours of therapy used in this study, which means that the symptoms were mild.
(SLGHPLRORJLFDO VWXGLHV KDYH LQ JHQHUDO LGHQWL¿HG some common threads between women with HG and other common nausea and vomiting syndromes like postoperative nausea and vomiting and chemotherapy related nausea and vomiting. 12 In a study done by Jee 13 on prophylactic antiemetic effects of combined treatment with ondansetron and dexamethasone with metoclopramide and dexamethasone in gynecologic patients receiving fentanyl iv-patient controlled analgesia, it was found that treatment with a combination of 20 mg metoclopramide and 5 mg dexamethasone was as effective to prevent postoperative nausea and vomiting syndrome as compared to treatment with 4 mg ondansetron and 5 mg dexamethasone. This data, if extrapolated to HG, can suggest that both drugs will be equally effective LQ +* ZKLFK LV VLPLODU WR WKH ¿QGLQJ RI RXU VWXG\ on HG.
There were a few limitations encountered in this study. Since a convenience sample was used with a small sample size, the results of the study need to be FRQ¿UPHG E\ ODUJHU SRZHUHG VWXG\ %OLQGLQJ ZDV QRW done, so there is possibility of bias.
CONCLUSIONS
Metoclopramide and ondansetron appeared to be equally effective to treat hyperemesis gravidarum. Although this was a prospective randomized controlled study, it had a small sample size and the UHVXOWV VKRXOG EH FRQ¿UPHG LQ D ODUJHU SRZHUHG VWXG\
DISCLOSURE
7KH DXWKRUV UHSRUW QR FRQÀLFWV RI LQWHUHVW LQ WKLV ZRUN
No violation of human rights and safety.
Funding: Nil
